Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration has extended the review period for the supplemental Biologics License Application (sBLA) for the once-weekly subcutaneous formulation of LEQEMBI IQLIK.
The new Prescription Drug User Fee Act (PDUFA) action date is now set for August 24, 2026.
The extension follows the FDA’s request for additional information, which the agency classified as a “major amendment” to the application. Importantly, the FDA stated that it has not identified any concerns regarding the approvability of the therapy as an initiation treatment for early Alzheimer’s disease.
The three-month extension is procedural rather than safety-related. According to Eisai and Biogen:
This type of extension is relatively common for complex biologics and allows the FDA additional time to fully assess the updated submission.
LEQEMBI is a monoclonal antibody targeting amyloid-beta plaques associated with Alzheimer’s disease. The therapy is currently approved for patients with:
The newly reviewed formulation, LEQEMBI IQLIK, is designed as a once-weekly subcutaneous injection, offering an alternative to intravenous infusions. Potential advantages include:
The FDA previously approved subcutaneous maintenance dosing in August 2025. The current sBLA focuses on using the injectable formulation as the starting treatment regimen.
Current anti-amyloid therapies often require frequent IV infusions, creating logistical challenges for patients, clinics, and healthcare systems.
A subcutaneous version could:
For Alzheimer’s disease, where ongoing treatment and caregiver involvement are critical, convenience can directly affect patient outcomes.
LEQEMBI has now received approvals in more than 50 countries and regions, including:
The therapy remains under review in several additional countries. Beyond the standard intravenous regimen, maintenance dosing approvals and filings continue expanding globally.
Lecanemab targets amyloid-beta protofibrils, which are believed to be among the most toxic forms of amyloid accumulation in Alzheimer’s disease. Researchers believe these protofibrils contribute to:
By reducing amyloid burden, LEQEMBI aims to slow disease progression during the early stages of Alzheimer’s disease.
Like other anti-amyloid monoclonal antibodies, LEQEMBI carries significant safety considerations.
The therapy includes a boxed warning for:
In rare cases, severe neurological complications and fatal intracerebral hemorrhage have occurred.
Patients carrying the ApoE ε4 genetic mutation—especially homozygotes—face substantially higher ARIA risk.
Reported in clinical studies:
Monitoring with periodic MRI scans remains a core part of treatment management.
The Alzheimer’s treatment landscape has rapidly evolved over the last few years, with anti-amyloid therapies becoming one of the industry’s most closely watched areas. LEQEMBI currently stands out due to:
The move toward subcutaneous administration could strengthen its competitive position further.
Eisai and Biogen continue evaluating lecanemab in additional studies, including:
Major ongoing programs include:
These studies aim to determine whether earlier intervention can further delay cognitive decline.
The FDA’s decision to extend the review timeline for LEQEMBI IQLIK does not appear to signal regulatory concern, but rather reflects the complexity of reviewing expanded biologics data.
For Eisai Co., Ltd. and Biogen Inc., approval of a once-weekly injectable initiation regimen could represent a major commercial and clinical milestone in Alzheimer’s disease treatment.
If approved, the subcutaneous formulation may significantly improve treatment flexibility and accessibility for patients navigating the early stages of Alzheimer’s disease.